Stay updated with breaking news from Deepak Bhatt. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Although the open-label trial has many limitations, it could add some support to findings from the REDUCE-IT study, which showed a reduction in cardiovascular events with high-dose eicosapentaenoic acid.
Experts grappled with how to understand the positive findings given that the trial missed its primary endpoint at 6 months.
A relatively high pacemaker rate remains a concern, particularly for younger patients, Robert Bonow said.
Experts grappled with how to understand the positive findings given that the trial missed its primary endpoint at 6 months.
Amarin Corporation Plc (NASDAQ:NASDAQ:AMRN) H.C. Wainwright Global Investment Conference September 12, 2022, 09:00 ET Company Participants Karim Mikhail - President, CEO & Director...